



Supplementary Figure 1. Changes of daily glyemic control in different subgroup. TIR, TBR, and TAR in patients with (A)TBR \geq 4%, (B)HbA1c \geq 7%, and (C)CV \geq 36% were also showed. Data are percentage.

Supplementary table 1. The proportions of hypoglycemic medications used at the endpoint.

| | Blinded FGM | Unblinded FGM | <i>P</i> value |
|---------------------------|-------------|---------------|----------------|
| Metformin (%) | 40(44.9%) | 37(44.6%) | 0.759 |
| Acarbose (%) | 25(28.1%) | 22(26.5%) | 0.865 |
| Insulin secretagogues (%) | 6(6.7%) | 4(4.8%) | 0.748 |
| DPP-4 inhibitors (%) | 18(20.2%)* | 22(26.5%)* | 0.369 |
| TZDs (%) | 2(2.2%) | 0(0%) | 0.498 |

Data are number (percentage); data were analyzed by chi-square tests; *, vs. baseline, $p<0.05$; DPP-4, dipeptidyl peptidase 4; TZDs, thiazolidinediones.

Supplementary table 2. Changes (endpoint minus baseline) of medications and lifestyles in patients with different problems of glucose control.

| | TBR $\geq 4\%$ | | HbA1c $\geq 7\%$ | | CV $\geq 36\%$ | |
|---------------------------------|-------------------|---------------------------------|------------------|------------------------------|------------------|-------------------------------|
| | Blinded | Unblinded | Blinded | Unblinded | Blinded | Unblinded |
| Number | 40 | 33 | 60 | 53 | 31 | 29 |
| HbA1c (%) | 0(-0.3,0.2) | -0.2(-0.5,0.1) | -0.5(-0.8,-0.2) | -0.7(-0.9,-0.4) [†] | 0(-0.3,0.4) | -0.4(-0.7,0) |
| Exercise time (min/day) | -14.8(-29.7,0.1) | 7.7(-0.4,15.9) [*] | -6.2(-17.1,4.7) | 9(-1.4,19.5) | -14(-32.5,4.5) | 5.9(-4.5,16.3) |
| Calories/weight daily (kcal/kg) | 4.1(1.4,6.8) | 0(-3.2,3.2) ^{*†} | 1.2(-1.5,3.9) | -1(-3.4,1.5) | 1.7(-1.9,5.4) | -0.7(-3.9,2.4) |
| Mean calories per meal (kcal) | 123.6(64.9,182.4) | 33.5(-36.8,103.9) ^{*†} | 4.0(-47.6,55.7) | -8.3(-60.6,44.0) | 78.5(-5.3,162.2) | 11.6(-64.1,87.3) |
| Carbohydrate (g)/day) | 22(-3.7,47.8) | 1.1(-15.6,17.9) | -14.3(-39,10.5) | -13.4(-31.5,4.6) | 9.2(-20.9,39.3) | -3.3(-23.9,17.3) |
| Daily meal frequency (number) | -0.3(-0.5,-0.1) | -0.1(-0.3,0.2) | -0.1(-0.3,0.1) | -0.1(-0.3,0.1) | -0.3(-0.5,0) | -0.1(-0.3,0.1) |
| Insulin dose (IU/day) | -1.2(-2.9,0.5) | -5.6(-8.5,-2.6) ^{*†} | -0.7(-2.5,1.1) | -1(-2.4,0.4) | -0.4(-1.9,1.1) | -4.4(-7.6,-1.2) ^{*†} |
| Metformin dose (g/day) | 0.1(0,0.2) | 0(-0.1,0.1) | 0.1(0,0.2) | 0(-0.1,0.1) | 0.1(0,0.2) | 0(-0.1,0.1) |
| Metformin (n) | 0 | 0 | 2 | 0 | 0 | 1 |
| Acarbose (n) | 5 | 0 | -4 | 3 | -5 | 3 |
| DPP-4 inhibitors (n) | 0 | 2 | 13 | 13 | 3 | 3 |

^{*}, for time×group in the mixed model ANOVA, $P < 0.05$; [†], for time in the mixed model ANOVA, $P < 0.05$